Alzheimer's disease: treatments in discovery and development.
Alzheimer's disease is the single biggest unmet medical need in neurology. Current drugs are safe, but of limited benefit to most patients. This review discusses the scientific basis and current status of promising disease-modifying therapies in the discovery and development stages. I describe the major targets of anti-amyloid therapy and the main focus of disease modification approaches. In addition, two new potential treatment approaches supported by retrospective epidemiology are outlined.
Citron
Martin
M
Amgen Inc., Department of Neuroscience, M/S 29-2-B, One Amgen Center Drive, Thousand Oaks, California 91320, USA. mcitron@amgen.com
D000544:Alzheimer Disease / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D015195:Drug Design; D004341:Drug Evaluation / Q000639:trends; D004345:Drug Industry / Q000639:trends; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans
D016229:Amyloid beta-Peptides; D004791:Enzyme Inhibitors